Business Combination - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended
	May 04, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock, shares issued		119,323,823		119,323,823		111,802,968
Decrease in deferred tax liability, measurement period adjustment				$ 200,000
Decrease in goodwill, measurement period adjustment				1,600,000
Increase of IPR&D, measurement period adjustment				1,400,000
Revenue		$ 31,516,000	$ 20,698,000	60,658,000	$ 59,850,000
Contributed net income (loss )		(32,157,000)	(34,274,000)	(49,577,000)	(59,324,000)
Kuur Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration		24,129,000		24,129,000		$ 24,076,000
Merger Agreement | Kuur Therapeutics, Inc.
Business Acquisition [Line Items]
Business acquisition, percentage of outstanding shares	100.00%
Upfront payment to stockholders in common stock	$ 70,000,000.0
Business acquisition, common stock issued	14,228,066
Business acquisition, share price	$ 3.71
Fair value of common stock	$ 52,786,000
Contingent consideration	19,839,000
Goodwill	28,711,000
Deferred tax liability	12,543,000
Revenue		100,000	0	100,000	0
Contributed net income (loss )		$ 3,700,000	$ 600,000	6,100,000	600,000
Acquisition-related costs				$ 0	$ 3,500,000
Merger Agreement | Kuur Therapeutics, Inc. | key Employees and Independent Directors
Business Acquisition [Line Items]
Transaction incentive liability	8,900,000
Cash paid related to transaction incentive liability	3,300,000
Common stock value paid related to transaction incentive liability	$ 5,600,000
Common stock, shares issued	1,373,601
Common stock price per share	$ 4.11
Merger Agreement | Kuur Therapeutics, Inc. | Maximum
Business Acquisition [Line Items]
Milestone payments payable	$ 115,000,000.0